What Is Sermorelin Peptide? (GHRH Analog Explained)

Sermorelin was a fully approved prescription drug before it stopped being one, and the reason had nothing to do with a safety scandal. Sermorelin acetate reached the US market under the brand name Geref in the 1990s, and the product was discontinued in 2008 in a decision reported as commercial rather than safety-driven. Most of the noise circulating about this compound today traces back to that single event.

Our team fields questions about this molecule constantly from labs sourcing GHRH analogs. The gap between what the published literature documents about the sermorelin peptide and what gets repeated in secondhand summaries is wide, and it almost always narrows to two variables: receptor specificity and half-life.

What is sermorelin peptide?

Sermorelin peptide is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), matching the first 29 residues of the native 44-amino-acid hormone. That fragment, known as GRF(1-29), is the shortest sequence retaining full activity at the GHRH receptor. It carries CAS number 86168-78-7 and is supplied strictly for laboratory research.

The most common oversimplification is treating the sermorelin peptide as a milder form of growth hormone. It isn't growth hormone at all. It's a secretagogue that acts one step upstream on the anterior pituitary rather than on peripheral tissue, which is why every serious comparison with recombinant hGH turns on regulation rather than raw potency. What follows covers the receptor mechanism, the real regulatory record, the half-life problem that shapes study design, and where the molecule sits against somatropin.

How A 29-Residue Fragment Drives The Pituitary

The sermorelin peptide binds the growth hormone-releasing hormone receptor (GHRHR), a Gs-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Binding activates adenylyl cyclase, which raises intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein), driving transcription of Pit-1, the transcription factor that governs growth hormone gene expression and somatotroph proliferation. Two distinct outputs follow: immediate release of stored GH, and slower synthesis of new GH.

Here's the part that gets lost. The sermorelin peptide cannot manufacture growth hormone. It asks a pituitary to release its own. Where the somatotroph population is depleted or the gland is structurally compromised, the literature describes the GHRH signal as largely ineffective, which is exactly why GHRH analogs were historically used as diagnostic agents to separate pituitary-origin deficiency from hypothalamic-origin deficiency.

Release also stays under two brakes. Somatostatin, the inhibitory hypothalamic hormone, suppresses GH secretion between pulses, and circulating IGF-1 (insulin-like growth factor 1) exerts negative feedback on the axis. Output therefore stays pulsatile rather than continuous. Research suggests this preserved pulsatility is the core reason GHRH analogs behave so differently from exogenous growth hormone in animal and cell models.

In our experience supplying GHRH analogs to research groups, pulsatility is the single variable most often missing from study designs that end up producing muddled data. Labs working with the sermorelin peptide who model it as a steady-state stimulus get results that don't replicate.

Regulatory Status: Approved Once, Discontinued Since

The sermorelin peptide is not an approved drug product in the United States today. Sermorelin acetate held FDA approval during the 1990s, marketed as Geref and Geref Diagnostic, for pediatric growth hormone deficiency and as a diagnostic agent assessing pituitary GH secretory capacity. Reporting around the 2008 discontinuation attributed the exit to commercial factors rather than to a safety withdrawal. So the plain answer to whether sermorelin is FDA approved: not currently, though it once was, and that history is why the question keeps resurfacing.

What exists now falls into three separate buckets, and conflating them causes most of the confusion. Compounding pharmacies operating under 503A and 503B frameworks prepare sermorelin, and compounded preparations are not FDA-approved drug products. Tesamorelin (Egrifta), a stabilized GHRH analog rather than sermorelin itself, does hold FDA approval for a defined indication, which keeps the GHRH class alive in regulatory discussion. And research-grade material is a third category entirely.

Sermorelin peptide sold by research suppliers, including Real Peptides, is research-use-only material. It is not intended for human or veterinary consumption and is not a substitute for an approved medicine. Nothing in this article is dosing, administration, or preparation guidance, because the sermorelin peptide is supplied for laboratory research use only.

What a procurement team should verify before buying: CAS 86168-78-7, the molecular formula C149H246N44O42S, a mass spectrometry result confirming molecular identity, and an HPLC purity figure on a batch-specific certificate of analysis. Identity verification is not paperwork theatre. It's the only defence against a mislabelled vial.

Why The Sermorelin Peptide Half-Life Shapes Every Study Design

The sermorelin peptide has a very short circulating half-life, reported in the literature in minutes rather than hours, because dipeptidyl peptidase-4 (DPP-4) cleaves the molecule at the N-terminal Tyr1-Ala2 bond almost immediately. That one enzymatic vulnerability explains the entire design history of the GHRH analog class.

Everything that came after sermorelin was engineered around that cleavage site. CJC-1295 without DAC, often labelled modified GRF(1-29), carries four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that block DPP-4 attack and resist trypsin cleavage and methionine oxidation. Tesamorelin attaches a trans-3-hexenoyl group to the N-terminus for the same protective reason. Sermorelin is the unmodified parent sequence, and its fragility is a property, not a defect.

The mistake we see most often isn't in handling, it's in comparison. Labs benchmark the sermorelin peptide against DPP-4-resistant analogs on peak GH response, find a lower number, and conclude sermorelin is simply weaker. Peak amplitude was never the differentiating variable. The real contrast is area under the curve versus pulse fidelity: a rapidly cleared GHRH signal produces a discrete pulse that resolves before somatostatin tone returns, while a resistant analog produces prolonged receptor occupancy and a flatter, less physiological exposure profile. If the research question concerns pulsatile signalling, the short half-life is the feature you're buying.

Handling follows from the same chemistry. Lyophilized peptide powder is comparatively stable, but it is hygroscopic and light-sensitive, and repeated freeze-thaw cycling degrades peptide integrity through aggregation and hydrolysis. Cold chain discipline during shipping and storage matters more for a 29-residue peptide than most first-time buyers expect.

Sermorelin Versus Recombinant HGH: What The Comparison Actually Turns On

The question of whether sermorelin is better than HGH has no clean answer because the two compounds answer different experimental questions. This table sets out how the sermorelin peptide differs from recombinant human growth hormone across the variables that genuinely change study outcomes.

What If: Scenarios In GHRH Analog Research

What if a study design calls for sustained GHRH receptor activation rather than a discrete pulse?

The unmodified GRF(1-29) sequence is the wrong tool for that question, and DPP-4-resistant analogs exist for exactly this reason. Sermorelin's rapid enzymatic clearance means receptor occupancy collapses within minutes, so any model requiring prolonged exposure will read as a null result rather than a negative one. The published literature on CJC-1295 without DAC and tesamorelin describes structural modifications designed around that clearance problem. Match the molecule to the exposure profile the hypothesis requires before ordering.

What if the lyophilized cake looks collapsed, shrunken, or discoloured on arrival?

Treat the vial as compromised and contact the supplier rather than proceeding with the experiment. A collapsed or melted cake usually indicates a temperature excursion in transit, and peptide degradation through aggregation or hydrolysis is not visually detectable once it has occurred. Appearance is a screening signal, not a verdict. The certificate of analysis reflects the batch at release, so any shipping event after that point sits outside its scope.

What if the certificate of analysis lists no CAS number or no purity method?

Don't proceed with procurement until identity documentation is supplied. A usable certificate names the compound, the batch, the CAS number, the analytical method used for purity, typically reverse-phase HPLC, and a mass spectrometry result confirming molecular weight against the expected value. A document showing a purity percentage with no stated method is an assertion, not data. Publicly published certificates, which Real Peptides maintains for its catalog, allow that verification to happen before an order rather than after.

The Honest Answer On Whether Sermorelin Is Worth It

Let's be direct about this: as a research tool, the sermorelin peptide earns its place because it is the reference GHRH sequence and every modified analog is measured against it. As a supposed upgrade over growth hormone, the framing is wrong. Sermorelin isn't a better version of somatropin, it's a different intervention point in the same axis, and asking which is superior is like asking whether a thermostat is better than a heater. The compound's value depends entirely on whether the research question concerns pulsatile pituitary signalling or downstream GH receptor activity.

Real Peptides supplies Sermorelin as small-batch synthesised, research-grade material with publicly verifiable documentation. The compound page sits at Sermorelin, batch records are published under certificates of analysis, and adjacent GHRH and secretagogue compounds are listed across the research catalog. All compounds are research use only.

The sermorelin peptide occupies a strange position in peptide science: too thoroughly characterised to be exotic, too commercially orphaned to be routine. A molecule that once carried an approval and then quietly lost it doesn't become less scientifically interesting, it becomes less commercially supported, and those are completely different things. That distinction is worth holding onto when reading the literature. Absence of a marketed product is not absence of evidence, and the GHRH signalling work published across the 1990s and 2000s didn't stop being valid the day Geref left the shelf.